Wednesday July 9, 10:08 am ET By Christopher Titus, CFA ArthroCare Corp. (NasdaqGS: ARTC - News) made a 30 percent round trip after solid first-quarter results, a string of product launches, and a recent acquisition that temporarily alleviated the stock's litigation overhang during the past quarter. However, our model continues to reflect higher litigation risk, related expenses, and a possible restatement that might follow. The stock remains a long-term Buy based on the company's long-term potential. The company has a clear strategy to leverage its patented Coblation technology and other innovative, clinically superior surgical devices for the treatment of soft-tissue conditions throughout the body. The company has operational efficiencies, in addition to top-line growth, to drive EPS gains. New products in Sports Medicine...
[read full story]
Your Web Site
